“What people in the [UK], and indeed international viewers, may be interested to know is that our MHRA … issued advice on benzodiazepine and opioids in March 2020, just before this guidance from NICE came out, and it’s diametrically opposed to this NICE guidance,” Clare Wills Harrison said.
Wills Harrison, a UK lawyer, has several legal cases where midazolam has clearly been misused. Midazolam seems to have been used in the UK the same way as remdesivir has been used in the USA so last week Dr. Bryan Ardis interviewed Wills Harrison.
As the interview covers a great deal of important information, we are taking extracts and publishing them in a series of articles. This article is the second in the series, the first can be read HERE. You can watch the full 90-minute discussion ‘UK Attorney, Clare Wills-Harrison, exposes “End of Life” drugs, protocols’ HERE.
In March 2020, the UK’s Medicines and Healthcare products Regulatory Agency (“MHRA”) issued a reminder of the risk of potentially fatal respiratory depression when benzodiazepines and opioids are used stating:
“We remind healthcare professionals that benzodiazepines and benzodiazepine-like drugs and opioids can both cause respiratory depression. When co-prescribed, the depressive effect on the central nervous system is additive. Therefore, they should only be co-prescribed if there is no alternative. Warnings about the risks of co-prescribing these products were reviewed in Europe in 2018.”
Read more: MHRA warns against using Midazolam while GMC encourages its use to treat Covid